Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630066 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT05630066 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 48 participants.
The verdict
NCT05630066, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion AS aged 5-17 years (inclusive) will be enrolled in the study.
Interventions
- DRUG Alogabat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2025-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05630066
The ClinicalTrials.gov registry entry for NCT05630066 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alogabat is the first listed.
NCT05630066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05630066 about?
NCT05630066 is a clinical study titled "A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.". This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion AS aged 5-17 years (inclusive) will be enrolled in the study.
What is the current status of trial NCT05630066?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2023-07-27. Estimated completion is 2025-12-02.
What interventions are being tested in trial NCT05630066?
The interventions under investigation include: Alogabat (DRUG).
Who is sponsoring clinical trial NCT05630066?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.